FDA Approved: JAKAFI — Supplemental Application (Incyte Corporation)

View source ↗

Summary

FDA approved a supplemental application for JAKAFI (ruxolitinib) submitted by Incyte Corporation, resulting in a label change and/or expanded indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Myelofibrosis
• Polycythemia Vera

Drugs mentioned

• Jakafi (ruxolitinib)

Snippet

SUPPL AP for JAKAFI (RUXOLITINIB)